Sylvie Négrier

33.1k citations
226 papers · 20.8k indexed · 8 hit papers · h-index 49

Impact in

Papers in

Sylvie Négrier

220 papers receiving 20.4k citations

Hit Papers

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial 2013 · 542 citations
542199820262007201610002.0k3.0k4.0k

Peers

Sylvie Négrier
Comparison fields: 5 of 139
  • Cancer Research 6.8k
  • Pulmonary and Respiratory Medicine 13.5k
  • Oncology 8.5k
  • Molecular Biology 11.0k
  • Immunology 2.0k
Replace Cezary Szczylik with:
Cezary Szczylik Poland
Thomas E. Hutson United States
M. Dror Michaelson United States
Stéphane Oudard France
Brian I. Rini United States
Christine Chevreau France
Tim Eisen United Kingdom
Olivier Rixe France
Joel Picus United States
Bradley C. Leibovich United States
Sylvie Négrier relative to Cezary Szczylik Poland Cezary Szczylik's profile →
Citations per field
00.5×1.5×2.3×
Cezary Szczylik · 1×
Citations per year

Countries citing papers authored by Sylvie Négrier

Since Specialization
Citations

This map shows the geographic impact of Sylvie Négrier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvie Négrier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvie Négrier more than expected).

Fields of papers citing papers by Sylvie Négrier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvie Négrier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvie Négrier. The network helps show where Sylvie Négrier may publish in the future.

Co-authors

The 25 scholars most cited alongside Sylvie Négrier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sylvie Négrier Line = papers co-authored together Sylvie Négrier links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20235
2 20237
3 20238
4 201916
5 201813
6
Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study
20141
7 201380
8
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
201221
9 2011148
10 2009378
11
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Hit paper breakdown →
20091711
12
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Hit paper breakdown →
2009864
13
EFFECT OF DOSE ON EFFICACY AND SAFETY IN IPILIMUMAB-TREATED PATIENTS WITH ADVANCED MELANOMA - RESULTS FROM A PHASE II, RANDOMIZED, DOSE-RANGING STUDY
20086
14 2007311
15
[Clinical practice guideline: 2005 update of recommendations for the management of patients with cutaneous melanoma without distant metastases (summary report)].
200620
16
[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site].
200217
17 199716
18 1997184
19 199431
20 198918

About Sylvie Négrier

Sylvie Négrier is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Nephrology and Molecular Biology, having authored 226 papers that have together received 20.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (137 papers), Renal and related cancers (60 papers), Cancer Immunotherapy and Biomarkers (55 papers), Cancer Genomics and Diagnostics (54 papers), Economic and Financial Impacts of Cancer (27 papers), Bladder and Urothelial Cancer Treatments (26 papers), Pancreatic and Hepatic Oncology Research (18 papers) and CAR-T cell therapy research (16 papers). The work is most often cited by research in Cancer Research (6.8k citations), Pulmonary and Respiratory Medicine (13.5k citations), Oncology (8.5k citations), Molecular Biology (11.0k citations) and Immunology (2.0k citations). Sylvie Négrier has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Ronald M. Bukowski, Thomas E. Hutson, Stéphane Oudard, Bernard Escudier, Cezary Szczylik, Robert J. Motzer, M. Dror Michaelson, Piotr Tomczak, Robert A. Figlin and Sindy T. Kim. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, European Journal of Cancer and Clinical Genitourinary Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026